The United Kingdom and the United States have finalized a key commercial pact that will maintain no duties on British pharmaceutical exports being sold in the US market.
The Terms of the Accord
As part of the deal, the UK has pledged to raise spending on drugs through the NHS. This pledge ensures that tariffs on these key goods will be held at zero for a duration of the next three years.
This agreement follows earlier threats to significantly raise duties on patented drug products, with increases mentioned reaching one hundred percent.
"This deal between the UK strengthens the global environment for cutting-edge drugs and establishes long-overdue balance to transatlantic medicine commerce," a statement said.
Commercial Significance
Drugs are one of the the United Kingdom's largest goods shipped to the US, which is clearly the primary buyer for large UK drugmakers.
Statistics indicate that in the year prior to September, the UK sold medicines valued at over eleven billion pounds to the US. This figure represented nearly one-fifth of total UK exports in that timeframe.
"This deal protects employment, boosts investment and paves the way for the UK to become a global hub for biotech and pharma," a government official commented.
Key UK Commitments
The agreement involves several specific commitments from the British government:
- Revised Affordability Limit: The UK will increase the price threshold at which it considers new therapies to be too expensive by a quarter.
- Increased NHS Spending: There is a goal to raise total health service expenditure on treatments from 0.3% of GDP to 0.6% over the coming ten years.
- Payback Limit: The percentage drug companies must return to the NHS to control costs will be capped at 15%. Previously, refunds were more than 20%.
Industry Background
This agreement follows a ongoing tension between the drug companies and the ministers over medicine costs and NHS adoption.
This friction were intensified by claims that American customers were paying significantly more for the same drugs than consumers in the Britain and the EU.
In recent months, several major pharmaceutical investments in the UK have been paused or cancelled, while multi-billion-dollar expansions have been pledged toward projects in the United States.
One official stated that the NHS must increase expenditure on treatments, noting that its spending on drugs had declined as a proportion of its resources over the previous ten-year period.
